How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/proteus-urinary-tract-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Proteus urinary tract infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proteus urinary tract infection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Proteus urinary tract infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Fetroja	CEFIDEROCOL	Shionogi	Cephalosporin Antibacterial		2019-01-01
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Maxipime	Cefepime Hydrochloride	Baxter	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Maxipime	CEFEPIME	Baxter	Cephalosporin Antibacterial		1996-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 13 drugs in Proteus urinary tract infection
Bristol-Myers Squibb · 4 drugs in Proteus urinary tract infection
Shionogi · 2 drugs in Proteus urinary tract infection
Pai Holdings Pharm · 2 drugs in Proteus urinary tract infection
Baxter · 2 drugs in Proteus urinary tract infection
Dr Reddys Labs Sa · 1 drug in Proteus urinary tract infection
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Proteus urinary tract infection
Generic (originally Roche) · 1 drug in Proteus urinary tract infection
Pfizer · 1 drug in Proteus urinary tract infection
Poitiers University Hospital · 1 drug in Proteus urinary tract infection
Sohag University · 1 drug in Proteus urinary tract infection
Sterimax · 1 drug in Proteus urinary tract infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Proteus urinary tract infection:

Cite this brief

Drug Landscape (2026). Proteus urinary tract infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/proteus-urinary-tract-infection. Accessed 2026-06-10.

Proteus urinary tract infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing